May 23, 2017

IVY and Immunomic Therapeutics to Host Cancer Moonshot Discussion

May 22, 2017

Immunomic Sr. Vice President to Speak at Skin Vaccination Summit 2017 in the Netherlands

May 18, 2017

Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™

May 15, 2017

Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting Cytomegalovirus (CMV)

April 26, 2017

Immunomic Vice President to Speak at Bio+Tech Conference 2017

April 21, 2017

Immunomic Therapeutics Announces Winner of Cancer Discovery Award

April 19, 2017

Immunomic CEO to Speak at 2017 BioHealth Capital Region Forum

April 12, 2017

Immunomic Scientist Dr. Yan Su to Speak at World Vaccine Congress

March 6, 2017

Immunomic CEO to Speak at European Life Science CEO Forum and Exhibition

February 2, 2017

Maryland Cancer Discovery Incubator Finalists Announced

January 5, 2017

Immunomic Therapeutics Announces Scientific Advisory Board Additions

December 20, 2016

Astellas’ peanut allergies DNA vaccine gains an FDA fast-track designation

December 14, 2016

Immunomic Therapeutics Announces Board Addition

November 22, 2016

Immunomic Therapeutics Announces Expansion of IP Portfolio

November 14, 2016

Tech Council of Maryland Announces Chairman and New Board Members

November 8, 2016

Immunomic Therapeutics Gives Back to Maryland Biotech Community

October 4, 2016

Immunomic Therapeutics (ITI) and Nature Technology Corporation (NTC) Jointly Announce Expanded Agreement

August 2, 2016

BHI Appoints New Board Members From Immunomic, Montgomery County

May 23, 2016

Immunomix CEO and Oncosec VP to Host Fireside Chat

May 16, 2016

Immunomic Therapeutics (ITI) Named “Company of the Year” by the Tech Council of Maryland

April 25, 2016

Immunomic Therapeutics (ITI) Delivering Closing Keynote Address at Wharton DC Innovation Summit

April 18, 2016

Immunomic Therapeutics (ITI) Featured at Maryland Regional Biotech Forum

March 29, 2016

Immunomic Therapeutics (ITI) and Lysosomal Associated Membrane Protein (LAMP) Based Nucleic Acid Immunotherapy Featured At 2016 World Vaccine Congress

January 14, 2016

Novel Platform Technology for Allergy & Cancer Immunology Featured at Biotech Showcase 2016

January 12, 2016

Media Invited: Immunomic Therapeutics, Inc. talks vital vaccine technology advancement at Biotech Showcase 2016

November 11, 2015

Johns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration

October 9, 2015

Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-vax platform to prevent and treat allergies

August 28, 2015

Immunomic Therapeutics, Inc. to Present at Skin Vaccination Summit in Switzerland

June 15, 2015

ITI Taps Micronaut to Visually Demonstrate Its LAMP-vax Programs

June 3, 2015

Immunomic Therapeutics, Inc. CEO, William Hearl, Ph.D. to Speak at 2015 BIO International Convention

May 13, 2015

Immunomic Therapeutics, Inc. Awarded $1.2M Department of Defense Grant for Development of ARA-LAMP-vax Peanut Allergy Vaccine

May 6, 2015

Immunomic Therapeutics Names Louise Peltier as Vice President, Regulatory Affairs

May 4, 2015

Immunomic Therapeutics Appoints Eric Winzer as Chief Financial Officer

April 2, 2015

Immunomic Therapeutics to Present at 15th Annual World Vaccine Congress

March 31, 2015

ITI Awarded SBIR Grant From NIH For Nanoplasmid Peanut Allergy Vaccine Development

March 25, 2015

ITI Receives Positive Feedback From FDA

March 9, 2015

ITI Present at BIO-Europe Annual Conference

March 3, 2015

ITI Explains Proprietary LAMP-vax Platform in Nature Advertorial Supplement

Feb 20, 2015

ITI to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 AAAAI Meeting

Feb 10, 2015

ITI Appoints Vice President of Operations

Jan 29, 2015

Astellas Pharma and Immunomic Therapeutics Announce Exclusive License for JRC2-LAMP-vax

Jan 09, 2015

ITI To Present at Biotech Showcase 2015

Dec 19, 2014

Bioject and Immunomic Therapeutics, Inc.

Dec 05, 2014

Significant Headway in Regulatory Interactions in Japan

Oct 28, 2014

Successful Completion of Series A Preferred Financing Round

Oct 01, 2014

ITI Filing an IND for a Phase II Study

Sep 17, 2014

ITI Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy

Aug 21, 2014

Relief for Allergy Sufferers Finally in Sight – Phase IC

Jun 29, 2014

Immunomic Therapeutics Engages Newport Coast Securities, Inc.

Jun 28, 2014

String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline

Jun 17, 2014

ITI Announces Significant Strides in Peanut Allergy Vaccine Development

May 19, 2014

ITI CEO Appointed to Panel at Prestigious Future in Review Conference

Apr 03, 2014

ITI Announces Data Analysis of Phase IB Study to Treat Japanese Red Cedar Allergy

Nov 07, 2013

ITI’s Process Development Laboratory at Hershey is Now Operational

Oct 22, 2013

ITI’s Medical Monitor, Dr. Lawrence Weiner, to Present at the 2013 ACAAI Annual Scientific Meeting

Jul 12, 2013

ITI Closes $3 Million Debt Pre-Series B Round

Jun 19, 2013

Myriad Supreme Court Case Has Promising Outcome for Immunomic Therapeutics

Apr 24, 2013

ITI Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy

Apr 10, 2013

ITI Announces Bernard C. Rudnick’s Nomination to the Board of Directors

Mar 25, 2013

ITI Has Generated More Than $6.5 Million in Funding To Date

Feb 22, 2013

ITI Receives Notice of Issuance for Chimeric Vaccines Patent

Jan 24, 2013

ITI Completes Patient Enrollment into Phase I protocol

Nov 5, 2012

Entering First Patients into Phase I protocol

Oct 25, 2012

New Process Development Laboratory at HCAR

Aug 2, 2012

Immunomic Therapeutics Receives Notice of Patent Allowance For Chimeric Vaccines, a Core Component of LAMP-Vax™ Vaccines

May 24, 2012

Immunomic Therapeutics’ CEO, Dr. William G. Hearl, to Present at the 2012 BIO International Convention in June

May 2, 2012

Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy

May 2, 2012

Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRCLAMP- Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy in JAPANESE

Apr 24, 2012

Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy

March 26, 2012

Filing of IND for JRC-LAMP-vax

Jan 9, 2012

Iti Secures Phase I Funding For Japanese Red Cedar Lamp Vaccine

Jan 1, 2012

LAMP Technology Promises Next Generation Vaccines to Improving Human Health

Apr 1, 2011

Immunomic Therapeutics Shareholders Elect Board, Barry McDonald as Chair.